[Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease]. / Sicherheitsaspekte parenteraler Eisentherapien bei Patienten mit chronischer Niereninsuffizienz.
Dtsch Med Wochenschr
; 138(24): 1312-7, 2013 Jun.
Article
em De
| MEDLINE
| ID: mdl-23737117
ABSTRACT
Iron deficiency often occurs in patients with chronic kidney disease and can be effectively treated with parenteral supplementation of iron. In these patients, prompt application of iron therapy can help to reduce the dependence of erythropoietin-stimulating agents and effectively treat anemia. Correct evaluation of iron metabolism in CKD patients can be difficult. Duration of and response to therapy should always be considered while planning parenteral supplementation of iron. The main safety aspects of parenteral iron preparations relate to their possible anaphylactic potential and the potential induction of oxidative stress due to the release of free iron. However, parenteral iron supplementation is usually safe and without major side effects. Regarding current data, none of the iron preparations is showing definitive superiority. Although uncommon, iron preparations containing dextran can lead to severe side effects, therefore these preparations appear to have an inferior safety profile. Due to limited data, a comparison of third-generation iron preparations with previous preparations is not possible. Recently, for the first time, the third generation iron preparation ferumoxytol has been directly compared to iron sucrose. From this data and others, it remains unclear whether third generation iron preparations show safety-relevant superiority.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Compostos de Ferro
/
Anemia Ferropriva
/
Falência Renal Crônica
Idioma:
De
Revista:
Dtsch Med Wochenschr
Ano de publicação:
2013
Tipo de documento:
Article